ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1603787
Cancer-specific senescence signature promotes malignant phenotypes and immunotherapy resistance in colorectal cancer
Provisionally accepted
- 1Department of Oncology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China
- 2Department of Oncology and Hematology, Fengdu General Hospital, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: While cellular senescence in colorectal cancer (CRC) exhibits strong correlations with immunotherapy response and clinical prognosis, its mechanistic basis remains elusive, and validated predictive biomarkers are currently unavailable.Methods: In this study, we integrated single-cell and bulk transcriptomic data to establish a cancer-specific senescence signature (CSS). Systematic biological characterization revealed that the CSS remodels the tumor microenvironment (TME), primarily through perturbed immune cell infiltration and CD8+ T-cell dysfunction. Functional validation via shRNA-mediated CD24 knockdown in HCT116 cells was corroborated by Western blot and flow cytometry. CD24 ablation’s effects on malignant phenotypes were assessed using colony formation, Transwell invasion, wound healing, and proliferation/apoptosis assays (Ki67/Annexin V/TUNEL). CSS-mediated CD8+ T-cell regulation was investigated using palbociclib-induced senescence models (HCT116/SW480). Potential senescence-targeting compounds were identified via the Cancer Therapeutics Response Portal (CTRP) and PRISM databases.Results: Our analyses validated the CSS as both a prognostic biomarker and immunotherapy predictor in CRC. CSS-high tumors displayed diminished cytotoxic T-cell infiltration and impaired CD8+ effector functions (reduced IFN-γ/granzyme B production), while CSS-low tumors showed enhanced T-cell activity. Mechanistic investigations revealed CSS-mediated immunosuppression via MHC class I dysregulation, compromising tumor antigen recognition. Genetic CD24 inhibition suppressed proliferation, migration/invasion and triggered apoptosis. Computational screening identified afatinib as a potent CSS-targeting agent, with in vitro studies confirming selective senescent cell growth inhibition through proliferation blockage and apoptosis induction. Notably, CSS-high status predicted immunotherapy resistance.Conclusion: Collectively, CSS drives tumor aggressiveness and independently predicts unfavorable survival outcomes and immunotherapy resistance in CRC. Notably, afatinib targeting of CSS selectively eliminated senescent cells via apoptosis while inhibiting tumor growth, highlighting its therapeutic potential for CSS-high malignancies.
Keywords: colorectal cancer, Immunotherapy resistance, senescence, prognosis, tumor immunity
Received: 15 Apr 2025; Accepted: 04 Jul 2025.
Copyright: © 2025 Wang, Ling, Huang, Luo and Duan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bixia Duan, Department of Oncology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.